Conducting business with #sustainability as a top priority allows Astellas to better serve patients and promote health and safety worldwide. We invite you to learn more about our annual performance data in our new Environment, Health, and Safety (#EHS) report, including progress we have made toward our commitment to achieve net zero greenhouse gas emissions by 2050 and short-term greenhouse gas emission reduction goals by 2030 which were certified by the Science Based Targets Initiative. These goals align with our belief that maintaining a healthy global environment is an essential part of building a sustainable society. Our commitment to disclose key environmental factors and address climate change issues also helped us earn a spot on CDP’s A List for our leadership in environmental transparency and climate change. Read the new EHS report: https://bit.ly/3MLW2Zu #NetZero #SBTi
概要
アステラス製薬は、最先端の「価値」駆使型ライフサイエンス・イノベーターを目指しています。革新的なサイエンスを患者さんにとって最良のアウトカムにつなげるために、医療変革の最前線で活動しています。世界約70か国で14,000人以上の従業員が勤務し、科学の進歩を追求し、アンメットメディカルニーズに応えるよう、事業活動に取り組んでいます。 このページ内でのコミュニケーションについては「アステラスグローバルLinkedInコミュニティガイドライン」をご覧ください。https://www.astellas.com/jp/global-linkedin-community-guidelines
- ウェブサイト
-
http://www.astellas.com/
アステラス製薬の外部リンク
- 業種
- 医薬品製造業
- 会社規模
- 社員 10,001名以上
- 本社
- Chuo-Ku、Tokyo
- 種類
- 上場企業
- 専門分野
- Pharmaceuticals、医薬品
場所
-
2-5-1, Nihonbashi-Honcho
Chuo-Ku、Tokyo、103-8411、JP
アステラス製薬の社員
-
Chad Stewart
Innovating Healthcare Strategy & Culture to improve peoples' lives and well-being
-
Jason Hill, Ph.D.
Precision Medicine
-
Achim v. Montigny
TALENTS & TECHNOLOGY FOR THE SUSTAINABLE & DATA-DRIVEN ENTERPRISE
-
Roderick P.
Director, EMEA Order to Cash Process Owner, Global Business Services
アップデート
-
We are headed to Barcelona for #ESMO24 September 13 – 17. If you’ll be there and want to learn more about Astellas and how our cutting-edge science transforms patients’ lives, meet us at booth 616. Connect with our HR and Astellas teams to learn how your skills can support our relentless pursuit of scientific progress and in tackling unmet medical needs. To learn more about Astellas and our open positions, visit https://lnkd.in/gxr6XSq2 Moitreyee Chatterjee-Kishore, Ph.D., MBA, Andrew Mortlock, Ahsan Arozullah, Tadaaki Taniguchi, Tywnia B., Rita Benavides
-
If you’re attending the European Congress of Pathology annual meeting, join us at Booth 16 to hear about our latest research in biomarkers and innovation in precision medicine. As part of our on-site activities, we are proud to sponsor a symposium – “The Pathologist's Loom: Weaving CLDN18.2 Into Practice” – on Tuesday, 10 September from 13:00-14:30 CEST. It will also be livestreamed via the virtual congress platform. For more insight into the potential of predictive biomarker CLDN18.2, including guidance on testing and scoring in patients with gastric or gastroesophageal junction adenocarcinoma, you can visit: https://lnkd.in/gnNHnBiJ #ECP2024 #Pathology #Biomarkers #PrecisionMedicine #GastricCancer
-
On Thursday, September 5, Astellas celebrated the opening of the Astellas Life Sciences Center (ALSC) in Cambridge, Massachusetts. Home of the first US-based open innovation SakuLab™, the new 62,000 square foot, LEED-certified facility allows us to connect with leading incubators, ambitious biotechnology start-ups and academia in one of the world’s leading life science ecosystems to foster the discovery and development of potential breakthrough therapies in areas of high unmet need. Read more about this important milestone for the organization here: https://lnkd.in/gwHbBg6q
-
We’re passionate about partnering with like-minded, ambitious innovators because we know collaboration helps bring groundbreaking therapies to patients, faster. If you are committed to pioneering science for patients in need, get in touch at #LSXUSA, Boston, MA, September 11-12 or reach out here: https://bit.ly/3MDzzOd #ScienceFirstForPatients #ChangingTomorrow
-
We are pleased to announce our new #collaboration agreement with BioLabs. This #partnership will enable us to leverage each other’s strengths and drive innovation in the healthcare industry. With this collaboration, we aim to accelerate the development of breakthrough solutions that will revolutionize healthcare and improve patient outcomes. #InnovationInBiotech
-
In 2024, Astellas received the highest rating of AAA (on a scale of AAA-CCC) in the MSCI ESG Ratings assessment for the first time. MSCI ESG Ratings aim to measure a company’s resilience to long-term, financially relevant Environmental, Social, and Governance risks. Astellas has been highly evaluated in entire ESG categories. As compared with last year, our efforts in addressing key issues of human capital development led to an increase in its score from AA to AAA at this time. As part of the Corporate Strategic Plan 2021, Astellas has established Organizational Health Goals and Strategic Goal 4 "Deepen our engagement in sustainability" and has been promoting sustainability efforts. We will continue to work to evolve the sustainability of both society and Astellas, ultimately aiming to sustainably increase our corporate value. Learn more about our commitment to ESG benchmarks and reporting for investors: https://bit.ly/3Tcpxrk #Sustainability #ESG #MSCI
-
Explore Astellas’ initiatives to bring DE&I to the workplace in Pharma Executive article by the executive editor, Mike Hollan. In the interview, Katsuyoshi Sugita, Astellas’ Chief People Officer and Chief Ethics & Compliance Officer, shares some examples including failure sharing sessions which encourage employees to try something new for bringing innovation and “imperfect English” policy he is promoting. Click on the link below to learn more: https://lnkd.in/gkgwzVsb #ExecutiveInterview #DiversityEquityInclusion
-
Estaremos no 29º Congresso Paulista de Obstetrícia e Ginecologia (SOGESP), que acontece de 22 a 24 de agosto em São Paulo. Na sexta-feira, dia 23, os profissionais médicos podem participar do simpósio promovido pela Astellas, “O que há de novo no tratamento dos sintomas vasomotores associados à menopausa: os inibidores do receptor NK3”, e se atualizar sobre a ciência por trás dos calores do climatério. Saiba mais em sogesp.com.br
-
Last week, our Chief Medical Officer Tadaaki Taniguchi sat down with EMJ GOLD for a podcast interview on his leadership journey. Learn more as he discusses how his experience as a surgical oncologist has inspired him to push boundaries for patients and Astellas’ ongoing commitment to pioneering new frontiers in oncology. Check out the full interview: https://lnkd.in/gYHjS6z9 #ScienceFirstForPatients #ChangingTomorrow